Sotera Health Co

Listed Company

SHCCIK 0001822479NasdaqLarge AcceleratedServices-Misc Health & Allied Services, NecDelawareFY ends Dec 31

Period

FY 2025

Revenue

$1.16B

Net Income

$77.95M

Total Assets

$3.26B

Equity

$606.03M

Shares Out

284.39M

Op. Cash Flow

$287.19M

Business

Sotera Health Co is a global provider of mission-critical end-to-end sterilization solutions, lab testing and advisory services for the healthcare industry. It offers terminal sterilization across multiple technologies (gamma, ethylene oxide, electron beam, X‑ray and emerging modalities), Co‑60 supply and gamma irradiation systems, outsourced microbiological and analytical laboratory testing, and technical and regulatory advisory services. The company operates through three principal businesses—Sterigenics (sterilization services), Nordion (Co‑60 and gamma systems) and Nelson Labs (testing and advisory). It serves medical device, pharmaceutical, food and specialty industrial customers through an international network of facilities and logistics channels spanning North America, Europe, Asia and other regions.

Summary from filing dated 2025-02-27

Financials

Consolidated Statement of Income

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Total net revenues	1,164	1,100	1,049	1,004	931
Total cost of revenues	518	498	472	447	413
Gross profit	646	602	577	557	519
Selling, general and administrative expenses	253	243	237	246	198
Amortization of intangible assets	31	62	64	63	64
Interest expense, net	156	165	143	80	74
Loss on refinancing of debt	1	24	0	0	—
Foreign exchange loss	947,000	199,000	159,000	145,000	1
Other income, net	−9	−5	−7	−6	−15
Income before income taxes	148	114	106	−243	176
Provision for income taxes	70	69	55	−10	59
Net income	78	44	51	−234	117
Pension and post-retirement benefits (net of taxes of $600, $2,804 and $(3,420), respectively)	2	8	−11	21	27
Interest rate derivatives (net of taxes of $(718), $(1,856) and $(5,467), respectively)	−2	−5	−16	21	404,000
Foreign currency translation	98	−119	40	−65	−16
Comprehensive income (loss)	176	−71	65	−257	127
Basic (in dollars per share)	0.27	0.16	0.18	−0.83	0.41
Diluted (in dollars per share)	0.27	0.16	0.18	−0.83	0.41
Basic (in shares)	284	283	281	280	279
Diluted (in shares)	286	285	283	280	279

Consolidated Balance Sheet

As of · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Cash and cash equivalents	345	277	296	395	107
Restricted cash short-term	2	2	5	1	7,000
Accounts receivable, net of allowance for uncollectible accounts of $2,968 and $2,532 as of December 31, 2025 and 2024, respectively	139	140	148	118	108
Inventories, net	54	49	48	37	54
Prepaid expenses and other current assets	65	51	54	81	72
Income taxes receivable	8	7	6	12	5
Total current assets	613	526	557	645	346
Property, plant, and equipment, net	1,131	1,037	947	775	651
Operating lease assets	33	28	24	26	40
Deferred income taxes	4	3	5	4	6
Post-retirement assets	54	43	28	36	5
Other assets	37	37	41	39	13
Other intangible assets, net	288	318	416	491	599
Goodwill	1,103	1,081	1,111	1,102	1,120
Total assets	3,263	3,072	3,130	3,118	2,790
Accounts payable	78	55	71	74	73
Accrued liabilities	125	90	122	490	62
Deferred revenue	18	15	14	12	9
Current portion of long-term debt	14	15	5	197	0
Current portion of finance lease obligations	3	3	9	2	1
Current portion of operating lease obligations	6	5	6	8	9
Income taxes payable	6	8	4	6	7
Total current liabilities	250	191	231	792	161
Long-term debt	2,127	2,208	2,224	1,747	1,744
Finance lease obligations, less current portion	94	95	64	57	41
Operating lease obligations, less current portion	30	24	20	22	33
Noncurrent asset retirement obligations	53	49	48	43	42
Deferred lease income	17	17	19	19	21
Post-retirement obligations	8	8	8	8	11
Noncurrent liabilities	7	4	9	13	16
Deferred income taxes	71	70	64	68	135
Total liabilities	2,657	2,667	2,687	2,767	2,203
See Commitments and contingencies note	—	—	—	—	—
Common stock, with $0.01 par value, 1,200,000 shares authorized; 286,037 shares issued at December 31, 2025 and 2024	3	3	3	3	3
Preferred stock, with $0.01 par value, 120,000 shares authorized; no shares issued at December 31, 2025 and 2024	0	0	0	0	0
Treasury stock, at cost (1,666 and 2,571 shares at December 31, 2025 and 2024, respectively)	−17	−23	−27	−30	−34
Additional paid-in capital	1,262	1,244	1,215	1,190	1,173
Retained deficit	−532	−610	−654	−706	−472
Accumulated other comprehensive loss	−110	−208	−93	−107	−84
Total equity	606	405	444	350	586
Total liabilities and equity	3,263	3,072	3,130	3,118	2,790

Consolidated Statement of Cash Flows

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Depreciation	95	84	77	64	64
Amortization of intangible assets	42	79	81	82	87
Deferred income taxes	22,000	9	3	−74	−4
Share-based compensation expense	31	37	32	21	14
Accretion expense	2	3	2	2	2
Unrealized foreign exchange loss (gain)	10	−18	6	−4	788,000
Unrealized (gain) loss on derivatives not designated as hedging instruments	−863,000	2	−2	3	−1
Amortization of debt issuance costs	5	7	9	6	6
Other	−4	−5	−5	−7	−13
Accounts receivable	7	2	−22	−13	−16
Inventories	−2	−5	−10	14	−20
Other current assets	−13	4	4	−6	−4
Accounts payable	5	−7	−5	1	20
Accrued liabilities	2	7	4	21	2
Income taxes payable / receivable, net	−5	1	924,000	−12	10
Other liabilities	295,000	−4	−2	383,000	−369,000
Other long-term assets	212,000	−7	−238,000	−5	−4
Net cash provided by (used in) operating activities	287	224	−148	278	282
Purchases of property, plant and equipment	−138	−179	−215	−182	−102
Other investing activities	3	74,000	69,000	32,000	−701,000
Net cash used in investing activities	−135	−179	−215	−182	−160
Proceeds from long-term borrowings	0	2,259	500	200	0
Payment of revolving credit facility	0	0	−200	0	0
Payments of debt issuance costs and debt discount	−4	−32	−26	−31,000	—
Payments of long-term borrowings	−86	−2,264	−3	0	−100
Buyout of leased facility	0	−7	0	0	—
Shares withheld for employee taxes on equity awards	−7	−4	−4	−393,000	−1
Other financing activities	−3	−2	−2	−2	−642,000
Net cash (used in) provided by financing activities	−101	−51	266	198	−117
Effect of exchange rate changes on cash and cash equivalents	16	−17	2	−4	44,000
Net increase (decrease) in cash and cash equivalents, including restricted cash	68	−23	−95	289	4
Cash paid during the period for interest	164	180	174	76	59
Cash paid during the period for income taxes, net of tax refunds received	61	66	50	75	52
Purchases of property, plant and equipment included in accounts payable	25	10	17	16	15

Filings

Filing historySign up free to browse every 10-K, 10-Q, 8-K, and proxy this filer has submitted to the SEC.Sign up free · Upgrade to Pro

Material Events

Material EventsTrack every 8-K filing and material event — AI-summarized, timelined, and alertable.Sign up free · Upgrade to Pro

Insiders

Insider ActivitySee executive buy/sell windows and insider trade activity over rolling 30/90/365-day windows.Sign up free · Upgrade to Pro

Institutional Holders

Institutional HoldersSee which funds hold this stock and track position changes quarter over quarter.Sign up free · Upgrade to Pro